List of Excipients in Branded Drug ALMOTRIPTAN MALATE

« Back to Dashboard

Generic Drugs Containing ALMOTRIPTAN MALATE

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	almotriptan malate	0093-5260	CELLULOSE, MICROCRYSTALLINE
Teva Pharmaceuticals USA Inc	almotriptan malate	0093-5260	CROSCARMELLOSE SODIUM
Teva Pharmaceuticals USA Inc	almotriptan malate	0093-5260	HYPROMELLOSE 2910
Teva Pharmaceuticals USA Inc	almotriptan malate	0093-5260	MANNITOL
Teva Pharmaceuticals USA Inc	almotriptan malate	0093-5260	POLYDEXTROSE

What are the Most Frequently-Used Excipients in ALMOTRIPTAN MALATE?

# Of NDCs	Excipient
2	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	HYPROMELLOSE
1	HYPROMELLOSE 2910
2	MANNITOL

Almotryptan Malate Excipient Strategy and Commercial Opportunities

Last updated: September 25, 2026

Almotriptan malate is an oral, immediate-release 5-HT1B/1D receptor agonist used for acute migraine treatment. Its excipient opportunity is primarily generic product differentiation rather than new-molecule exclusivity. The strongest commercial options are low-cost film-coated tablets, orally disintegrating tablets, rapidly dispersing tablets, and patient-friendly formulations designed for migraine-associated nausea.

The reference product, Axert, established a conventional tablet platform using mannitol, microcrystalline cellulose, povidone, sodium starch glycolate, magnesium stearate, and a film-coating system. Generic manufacturers can compete through manufacturing efficiency, supply reliability, packaging, tablet size, dose flexibility, and alternative dosage forms rather than through a materially novel excipient system.

What is almotriptan malate and how is it administered?

Almotriptan malate is the malate salt of almotriptan. It is approved in the United States for the acute treatment of migraine attacks in adults and adolescents aged 12 years and older. The approved strengths are 6.25 mg and 12.5 mg almotriptan tablets. The drug is taken orally, with or without food, and is not intended for migraine prophylaxis or cluster-headache treatment. [1]

Attribute	Product information
Active ingredient	Almotriptan malate
Pharmacologic class	Selective serotonin 5-HT1B/1D receptor agonist
Reference product	Axert
Dosage form	Immediate-release oral tablet
Strengths	6.25 mg and 12.5 mg
Key indication	Acute treatment of migraine with or without aura
U.S. regulatory pathway	Original NDA and subsequent ANDA generic pathway
Biologic risk	None; almotriptan is a small molecule
Biosimilar exposure	None
Primary formulation challenge	Rapid, reproducible oral disintegration without excessive friability or poor taste

What excipients protect the reference almotriptan tablet?

The Axert labeling identifies a conventional direct-compression or granulated immediate-release tablet system. The inactive ingredients listed for the reference product include mannitol, microcrystalline cellulose, povidone, sodium starch glycolate, and magnesium stearate. The film coating contains hypromellose, titanium dioxide, polyethylene glycol, and talc. Manufacturer-specific generic formulations may use different excipients within the same functional categories. [1,2]

Functional role of the principal excipients

Excipient	Functional role	Commercial relevance
Mannitol	Diluent and mouthfeel modifier	Supports low-density tablets and can improve palatability
Microcrystalline cellulose	Filler and dry binder	Improves compressibility and tablet mechanical strength
Povidone	Binder	Supports granule strength and content uniformity
Sodium starch glycolate	Superdisintegrant	Promotes rapid tablet breakup after ingestion
Magnesium stearate	Lubricant	Reduces ejection force and tooling friction
Hypromellose	Film former	Provides coating integrity and appearance
Titanium dioxide	Opacifier and pigment	Controls tablet appearance and light protection
Polyethylene glycol	Plasticizer	Improves coating flexibility
Talc	Anti-tacking and coating aid	Reduces coating adhesion during processing

The formulation is commercially efficient because it uses widely available, compendial excipients with established regulatory histories. That reduces supply-chain risk and limits the need for novel excipient justification.

What formulation opportunities exist for almotriptan malate?

The main formulation opportunity is to improve usability during migraine attacks. Migraine patients may experience nausea, vomiting, photophobia, and difficulty swallowing. An excipient strategy that reduces water dependence or tablet-swallowing burden can create practical differentiation.

Immediate-release film-coated tablets

A standard film-coated tablet remains the lowest-risk commercial option. Generic sponsors can optimize:

• Tablet weight and size.
• Disintegration time.
• Compression force.
• Dose uniformity at the 6.25 mg strength.
• Coating durability.
• Color differentiation between strengths.
• Blister packaging for portability.
• Moisture protection during shelf life.

The critical balance is between mechanical strength and rapid disintegration. Excessive magnesium stearate or over-lubrication can slow wetting and dissolution. Excessive compression can produce hard tablets that pass friability testing but disintegrate too slowly.

Orally disintegrating tablets

An orally disintegrating tablet, or ODT, is the most commercially relevant differentiated platform. Potential excipient systems include:

• Mannitol for a cooling mouthfeel and low hygroscopicity.
• Crospovidone or sodium starch glycolate for rapid disintegration.
• Low-substituted hydroxypropyl cellulose for swelling and wicking.
• Microcrystalline cellulose or silicified microcrystalline cellulose for structure.
• Crospovidone combined with porous carriers for rapid liquid penetration.
• Sweeteners and flavors to address bitterness.
• Low-moisture film or blister packaging to protect tablet integrity.

An ODT would need careful taste-masking work. Almotriptan salt formulations can produce an undesirable taste profile, and a high-solubility dosage form may increase immediate exposure to the oral cavity. Commercial approaches include polymeric taste-masking, ion-exchange resins, coated drug particles, or compression of coated microparticles.

An ODT may require an ANDA if the product meets the applicable sameness and bioequivalence requirements. A materially different formulation, delivery mechanism, or labeling package may require a 505(b)(2) application. FDA’s product-specific requirements and the reference listed drug’s dosage-form attributes determine the regulatory route. [3,4]

Fast-dispersing and effervescent formats

Fast-dispersing tablets can target patients who need administration without water but do not require a formal ODT platform. Effervescent tablets or powders are technically possible but less attractive because they introduce:

• Moisture sensitivity.
• Packaging complexity.
• Sodium or potassium load.
• Larger dose units.
• More difficult patient handling during migraine episodes.

Powder-filled sachets or orally consumable granules could reduce tablet-swallowing difficulty, but they would face taste, dose uniformity, and packaging challenges. These formats are better suited to a 505(b)(2) strategy than to a straightforward low-cost generic program.

How should manufacturers design the excipient system?

The preferred development strategy is to begin with a reference-like immediate-release tablet and then assess a differentiated dosage form as a second product.

Recommended screening matrix

Development variable	Typical evaluation
Diluent	Mannitol versus lactose-free cellulose systems
Binder	Povidone grade and concentration
Disintegrant	Sodium starch glycolate versus crospovidone
Lubricant	Magnesium stearate level and blending time
Taste masking	Polymer coating, resin complex, or flavor system
Coating	Hypromellose-based versus minimal-coat tablet
Packaging	HDPE bottle with desiccant versus alu-alu blister
Performance	Disintegration, dissolution, friability, hardness, stability
Regulatory	ANDA sameness versus 505(b)(2) differentiation

The highest-risk variables are lubricant level, disintegrant distribution, drug particle size, and moisture exposure. These parameters can materially affect dissolution. A development program should test dissolution across multiple pH conditions and include aged stability samples rather than relying only on release testing.

What FDA regulatory status applies to almotriptan malate?

Axert was approved by FDA as an NDA product. Generic almotriptan products may be approved through ANDAs referencing the listed drug. The relevant regulatory issues are:

1. Pharmaceutical equivalence to the reference product.
2. Bioequivalence.
3. Same dosage form and route of administration for an ANDA.
4. Acceptable inactive ingredients for the proposed route and dosage form.
5. Adequate stability and manufacturing controls.
6. Appropriate labeling for acute migraine treatment.

An ODT or other non-reference dosage form may not automatically qualify for a conventional ANDA. The commercial advantage of a differentiated formulation must be weighed against the added clinical, bioequivalence, CMC, and labeling requirements.

What is the Orange Book and patent status of almotriptan?

The U.S. Orange Book identifies approved drug products, therapeutic equivalence evaluations, and listed patent or exclusivity information. Almotriptan is a small-molecule product and has no biosimilar pathway. Any commercial assessment should distinguish between:

• FDA approval status.
• Current Orange Book listings.
• Expired composition-of-matter rights.
• Any remaining formulation or method-of-use listings.
• ANDA paragraph IV certifications.
• State-specific substitution and launch timing.

The original U.S. almotriptan patent estate is historical rather than a major current barrier to generic entry. The principal commercial risk is therefore regulatory execution, manufacturing cost, supply continuity, and market access. Current Orange Book records should control any launch-date or litigation conclusion. [5]

What patent risks affect excipient-based products?

Excipient selection by itself usually does not create strong exclusivity. Patent risk may arise from:

• A specific ODT architecture.
• Taste-masked almotriptan particles.
• A defined polymer-drug complex.
• A multiparticulate or orally disintegrating delivery system.
• A controlled-release formulation.
• A manufacturing process with defined granulation or coating parameters.
• A packaging configuration tied to stability performance.

A sponsor seeking formulation exclusivity would need claims directed to the combination of almotriptan, excipient identity, concentration range, particle structure, dissolution profile, and clinical or stability benefit. Broad claims to conventional mannitol, cellulose, povidone, or magnesium stearate systems are unlikely to provide durable protection because those materials are widely used in oral solid dosage forms.

When does almotriptan lose exclusivity?

Almotriptan’s original U.S. market exclusivity and primary patent protection have expired. The product is therefore exposed to generic competition, and commercial value depends on product execution rather than originator exclusivity.

The reference product’s historical exclusivity timeline is summarized below.

Event	Timing
FDA approval of Axert	2001
Original branded exclusivity period	Expired
Original patent protection	Expired
Generic market opportunity	Open, subject to current FDA approval and Orange Book status
Biosimilar pathway	Not applicable
Current commercial protection	Potentially limited to product, process, formulation, trademark, or contractual rights

Which companies are challenging or competing with Axert?

Competition comes primarily from generic manufacturers and from other triptans. Relevant competing products include sumatriptan, rizatriptan, zolmitriptan, naratriptan, frovatriptan, and eletriptan. Almotriptan competes on tolerability, response, dosing convenience, payer coverage, and generic price.

Product	Active ingredient	Common dosage forms	Competitive position
Axert and generics	Almotriptan	Immediate-release tablet	Generic-led, oral tablet market
Imitrex and generics	Sumatriptan	Tablet, nasal spray, injection	Broadest route-of-administration competition
Maxalt and generics	Rizatriptan	Tablet, ODT	Direct ODT and migraine convenience competition
Zomig and generics	Zolmitriptan	Tablet, nasal spray, ODT	Alternative non-tablet and ODT positioning
Relpax and generics	Eletriptan	Tablet	Oral triptan competitor
Frova and generics	Frovatriptan	Tablet	Longer half-life positioning
Amerge and generics	Naratriptan	Tablet	Oral generic competitor

Rizatriptan and zolmitriptan are the most relevant formulation comparators because they have marketed ODT options. Their excipient and packaging strategies provide a benchmark for patient-centered migraine dosage forms, although their pharmacokinetic and regulatory requirements cannot be assumed to apply directly to almotriptan.

What generic launch risks exist?

A conventional almotriptan tablet has moderate technical risk and relatively high price pressure. The main launch risks are:

• Low wholesale acquisition price.
• Multiple approved generic suppliers.
• Limited brand loyalty after patent expiry.
• Payer preference for lower-cost triptans.
• Small absolute market compared with sumatriptan.
• Dose-uniformity challenges at the 6.25 mg strength.
• Stability risks from moisture-sensitive disintegrants or coatings.
• Difficulty achieving a meaningful premium for an ODT.
• Packaging cost that exceeds the value of the patient benefit.

A differentiated ODT can improve market positioning but may not support a premium unless it demonstrates clear patient or payer value. The strongest initial target is a compact, rapidly disintegrating, taste-masked product in unit-dose blister packaging.

How strong is the almotriptan formulation opportunity?

The opportunity is commercially viable but not based on conventional excipient patent protection. The best strategy is a two-tier portfolio:

1. A low-cost, reference-like film-coated tablet for volume and formulary access.
2. A differentiated ODT or fast-dispersing tablet for convenience-sensitive patients.

The reference-like product should prioritize reliable supply, high yield, low tablet weight, and robust dissolution. The differentiated product should prioritize taste masking, rapid disintegration, unit-dose portability, and a defensible formulation profile.

What licensing opportunities exist?

Licensing opportunities are most likely in formulation technology rather than in the active ingredient. Potential targets include:

• Taste-masking platforms for bitter or rapidly dissolving salts.
• ODT compression technologies.
• Drug-resin complexes.
• Spray-dried polymeric dispersions.
• Low-moisture blister systems.
• Pediatric-friendly flavoring platforms.
• Continuous manufacturing processes for low-dose tablets.

A license is more attractive when it provides documented bioequivalence support, scalable manufacturing, freedom-to-operate analysis, and a patent position extending beyond the use of standard excipients. A simple excipient substitution is unlikely to justify a significant royalty burden in a generic migraine market.

Key Takeaways

• Almotriptan malate is a small-molecule migraine drug with no biosimilar exposure.
• The reference product uses a conventional immediate-release tablet excipient system.
• Mannitol, microcrystalline cellulose, povidone, sodium starch glycolate, and magnesium stearate are central formulation components.
• The strongest differentiated opportunity is an orally disintegrating or rapidly dispersing tablet.
• Taste masking, moisture protection, and tablet robustness are the main technical issues.
• Conventional excipient selection is unlikely to create strong standalone patent protection.
• U.S. commercial competition is generic-led, with sumatriptan, rizatriptan, and zolmitriptan as major formulation comparators.
• A dual-product strategy, combining a low-cost tablet with a patient-friendly ODT, offers the clearest commercial path.
• Licensing value is concentrated in delivery, taste-masking, packaging, and manufacturing technology.
• Current FDA Orange Book records and approved-product labeling control any final assessment of live patents, listings, or launch restrictions.

FAQs

Can almotriptan malate be formulated without lactose?

Yes. The reference formulation uses mannitol and microcrystalline cellulose rather than relying on lactose. Lactose-free generic tablets can therefore be developed without creating a major formulation departure.

Is an almotriptan ODT automatically eligible for an ANDA?

No. Eligibility depends on the reference product, dosage-form requirements, pharmaceutical equivalence, bioequivalence, and FDA guidance. A materially different delivery system may require a 505(b)(2) application.

Which excipient is most important for rapid almotriptan disintegration?

The disintegrant system is central, but performance also depends on compression force, lubricant concentration, tablet porosity, drug particle size, and moisture content. Sodium starch glycolate and crospovidone are practical candidates for comparative development.

Can an almotriptan formulation patent extend market exclusivity?

A formulation patent can create additional protection if it claims a specific and non-obvious dosage form, particle structure, excipient combination, process, or performance profile. Conventional use of standard tablet excipients is unlikely to provide broad protection.

Is pediatric almotriptan formulation development commercially attractive?

The approved indication includes adolescents aged 12 years and older. A smaller, taste-masked tablet or ODT could improve administration, but the commercial opportunity is constrained by the generic market, competing triptans, and the need to support age-appropriate labeling and palatability.

References

1. U.S. Food and Drug Administration. (2001). Axert (almotriptan malate) tablets prescribing information. FDA.
2. National Library of Medicine. (n.d.). DailyMed: Almotriptan malate tablet, film coated. U.S. National Library of Medicine.
3. U.S. Food and Drug Administration. (2023). Abbreviated new drug application submissions: Refuse-to-receive standards. FDA.
4. U.S. Food and Drug Administration. (2024). Product-specific guidances for generic drug development. FDA.
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.